Apoptotic rate in patients with myelodisplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines

Journal of Cellular and Molecular Medicine

Volumn 7, Issue 3, 2003, Pages 313-321

  Moldoveanu, Elena ^a   Moicean, Andreea ^b   Vidulescu, Cristina ^c   Marta, Daciana ^a   Colita, Adriana ^b  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Apoptosis; Bcl 2; Cytokines; Myelodisplastic syndrome

Indexed keywords

AMINOTRANSFERASE; BIOTIN; CIPROFLOXACIN; CYTOKINE; DEXAMETHASONE; LIPOCORTIN 5; PENTOXIFYLLINE; PEROXIDASE; PROTEIN ANTIBODY; PROTEIN BCL 2; PYRIDOXINE; STREPTAVIDIN;

ADULT; APOPTOSIS; ARTICLE; BLOOD TRANSFUSION; BONE MARROW; CELL BUDDING; CELL MEMBRANE; CELL NUCLEUS MEMBRANE; CELL ULTRASTRUCTURE; CHEMICAL ANALYSIS; CHROMATIN CONDENSATION; CLINICAL ARTICLE; CONJUGATE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; DRUG RESPONSE; ELECTRON MICROSCOPY; EVALUATION; FEMALE; HEMATOPOIETIC CELL; HODGKIN DISEASE; HUMAN; HUMAN CELL; LIVER TOXICITY; MALE; MODULATION; MYELODYSPLASTIC SYNDROME; PARAMETER; PATIENT; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REFRACTORY ANEMIA; SAMPLE; TREATMENT OUTCOME;

APOPTOSIS; BONE MARROW CELLS; CYTOKINES; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS;

EID: 0242690968     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2003.tb00232.x     Document Type: Article

References (33)

1. Kouides P.A., Bennett J.M., Understanding the myelodysplastic syndromes, Oncologist, 2:389-401, 1997
2. List A., Jacobs A., Biology and pathogenesis of the myelodysplastic syndromes, Sem. Oncol., 19: 14-24, 1992
3. Delforge M., Verhoef G., Boogaerts M., Understanding the pathogenesis of myelodysplastic syndromes. In: Educational Book ed. by Fifth Congress of the European Haematology Association, Birmingham, 2000, pp.82-86
4. Garandeau C., Pautas E., Andreux M., Andreux J., Gaussemet P., Siguretal V., Myelodysplastic syndromes, Annales de Biologie Clinique, 58 :405-16, 2000
5. Hellstrom-Lindberg E., Willman C., Barrett A.J., Saunthararajah Y., Achievements in understanding and treatment of myelodysplastic syndromes, Haematology, 1: 110, 2000
6. Nosslinger T, Reisner R, Koller E, Grüner H, Tüchler H, Nowotny H, Pittermann E, Pferlstöcker M., Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution, Blood, 98:2935-2941,2001
7. Heaney M.L., Golde D.W., Myelodysplasia, N. Engl. J. Med., 340: 1649-1660, 1999
8. Hellström-Lindberg E., Treatment of adult myelodysplastic syndromes, Int. J. Hematol., 70: 141-154, 1999
9. Dansey R., Myelodysplasia, Curr. Opin. Oncol., 12: 13-21, 2000
10. Greenberg P.L., Apoptosis and its role in the myelodysplastic syndrome: implication for disease natural history and treatment, Leuk. Res., 22:1123-36, 1998
11. Martin S.J., Green D.R., Cotter T.G., Dicing with death: dissecting the components of the apoptosis machinery, Trends Biochem. Sci., 19: 26-30, 1994
12. Mignotte B., Vayssiere J.L., Mitochondria and apoptosis, Eur. J. Biochem., 252: 1-15, 1998
13. Thompson C.B., Apoptosis in the pathogenesis and treatment of disease, Science, 267: 1456-1462, 1995
14. Osborne B.A., Schwartz L.M., Essential genes that regulate apoptosis, Trends Cell. Biol., 4: 394-403, 1994
15. Rinkenberger J.L., Korsmeyer S.J., Errors of homeostasis and deregulated apoptosis, Curr Opin Genet Dev., 7:589-596, 1997
16. Stewart B.W., Mechanism of apoptosis, integration of genetic, biochemical and cellular indicators, J. Natl. Cancer. Inst., 86 :1286-1292, 1994
17. Lopez-Farre A., Rodriguez-Feo J.A., Sanchez de Miguel L., Rico L., Casada S., Role of nitric oxide in the control of apoptosis in the microvasculature, Int. J. Biochem. Cell. Biol., 30: 1095-1106, 1998
18. 3 only Proteins and more, Annu. Rev. Immunol. 21: 71-105, 2003
19. Borner C., Diminished cell proliferation associated with the death-protective activity of Bcl-2, J. Biol. Chem., 271: 12695-21698, 1996.
20. Furukawa Y., Iwase S., Kikuchi J., Teruiet Y, Nakamura M, Yamada H, Kano Y, Matsuda M, Phosphorylation of Bcl-2 protein by cdc2 kinase during G2/M phases and its role in cell cycle regulation, J. Biol. Chem., 275: 21661-21667, 2000.
21. Kitagawa M., Saito I., Kuwata T., Yoshida S., Yamaguchi S., Takahashi M., Tanizawa T., Kamiyama R., Hirokawa K, Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes, Leukemia, 11: 2049-2054, 1997
22. Gersuk G.M., Beckham C., Loken M.R., Kiener P., Anderson J.E., Farrand A., Troutt A.B., Ledbetter J.A., Deeg H.J., A role for tumour necrosis factor-α, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome, Br. J. Haematol. 103: 179-188, 1998
23. Mundle S.D., Reza S., Ali A., Mativi Y., Shetty V., Venugopal P., Gregory S.A., Raza A., Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes, Cancer Lett., 140: 201-207, 1999
24. Deeg H.J., Beckham C., Loken M.R., Bryant E., Lesnikova M., Shulman H.M., Gooley T., Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome, Leuk. Lymphoma, 37: 405-414, 2000
25. Greenberg P.L., Cox C., LeBeau M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J., International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89: 2079-2088, 1997
26. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C., Proposals for the classification of the myelodysplastic syndromes, Br. J. Haematol., 51: 189-199, 1982
27. Marta D., Gãbreanu A., Moldoveanu E., Ultrastructural and biochemical evaluation of apoptosis using annexin V, Rom. J. Physiol., in press.
28. Greenberg P.L., Young N.S., Gattermann N, Myelodysplastic syndromes, Haematology, 1:136-161, 2002
29. Raza A., Qawi H., Lisak L., Andric T., Dar S., Andrews C., Venugopal P., Gezer S., Gregory S., Loew J., Robin E., Rifkin S., Hsu W.T., Huang R.W., Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxyphylline, and ciprofloxacin with or without dexamethasone, Blood, 96: 1580-1587, 2000
30. Bouscary D., Chen Y.L., Guesnu M., Picard F., Viguier F., Lacombe C., Dreyfus F., Fontenay-Roupie M., Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro, Exp. Hematol., 28: 784-91, 2000
31. Bellamy W.T., Richter L., Sirjani D., Roxas C., Glinsmann-Gibson B., Frutiger Y., Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes, Blood, 97: 1427-1434, 2001
32. Kurotaki H., Tsushima Y., Nagai K., Yagihashi S., Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia, Acta Haematologica, 102: 115-123, 2000
33. Parker J.E., Fishlock K.L., Czepulkowski B., Pagliuca A., Mufti G.J., "Low-risk" myelodysplastic syndromes is associated with excessive apoptosis and an increased ratio of pro-versus anti-apoptotic bcl-2-related proteins, Br. J. Haematol., 103:1075-1082, 1998